EP1578996A4 - Compositions et methodes pour diagnostiquer et traiter des tumeurs - Google Patents

Compositions et methodes pour diagnostiquer et traiter des tumeurs

Info

Publication number
EP1578996A4
EP1578996A4 EP03813488A EP03813488A EP1578996A4 EP 1578996 A4 EP1578996 A4 EP 1578996A4 EP 03813488 A EP03813488 A EP 03813488A EP 03813488 A EP03813488 A EP 03813488A EP 1578996 A4 EP1578996 A4 EP 1578996A4
Authority
EP
European Patent Office
Prior art keywords
diagnosing
compositions
methods
treating tumors
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03813488A
Other languages
German (de)
English (en)
Other versions
EP1578996A2 (fr
Inventor
Thomas D Wu
Yan Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of EP1578996A2 publication Critical patent/EP1578996A2/fr
Publication of EP1578996A4 publication Critical patent/EP1578996A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03813488A 2002-10-18 2003-10-15 Compositions et methodes pour diagnostiquer et traiter des tumeurs Withdrawn EP1578996A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41898802P 2002-10-18 2002-10-18
US418988P 2002-10-18
PCT/US2003/029126 WO2004060270A2 (fr) 2002-10-18 2003-10-15 Compositions et methodes pour diagnostiquer et traiter des tumeurs

Publications (2)

Publication Number Publication Date
EP1578996A2 EP1578996A2 (fr) 2005-09-28
EP1578996A4 true EP1578996A4 (fr) 2007-12-19

Family

ID=32712943

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03813488A Withdrawn EP1578996A4 (fr) 2002-10-18 2003-10-15 Compositions et methodes pour diagnostiquer et traiter des tumeurs

Country Status (5)

Country Link
EP (1) EP1578996A4 (fr)
JP (1) JP2006516192A (fr)
AU (1) AU2003303144A1 (fr)
CA (1) CA2503043A1 (fr)
WO (1) WO2004060270A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
EP1562969A4 (fr) * 2002-03-28 2006-07-05 Bristol Myers Squibb Co Nouvelle proteine de surface cellulaire avec replis d'hemoglobine, bgs-19
WO2003091402A2 (fr) * 2002-04-23 2003-11-06 University Of Georgia Research Foundation, Inc. Sequence de codage de n-acetylglucosaminyltransferase vb, cellules recombinantes et procedes associes
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1584684A1 (fr) * 2004-02-20 2005-10-12 Samsung Electronics Co., Ltd. Protéine associée au cancer du sein, gène la codant et méthode de diagnostique du cancer du sein utilisant ladite protéine et ledit gène
JP4468989B2 (ja) 2004-08-16 2010-05-26 クアーク・ファーマスーティカルス、インコーポレイテッド Ｒｔｐ８０１阻害剤の治療への使用
GB0422211D0 (en) * 2004-10-06 2004-11-03 Randox Lab Ltd Method
EP1812794A4 (fr) * 2004-10-13 2008-09-10 A & G Pharmaceutical Inc Recepteurs de facteurs de croissance d'autocrine et methodes
JP2007008844A (ja) * 2005-06-29 2007-01-18 Nippon Flour Mills Co Ltd セプチン２タンパク質と特異的に反応するモノクローナル抗体、それを産生するハイブリドーマ、癌の検出方法及び癌の検出用キット
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
US20070237713A1 (en) 2006-04-04 2007-10-11 Fan Rong A PCan065 Antibody Compositions and Methods of Use
GB2450840B (en) 2006-05-11 2010-12-29 Quark Pharmaceuticals Inc Screening Systems Utilizing RTP801
CN103424541B (zh) * 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
WO2007141796A2 (fr) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Utilisations thérapeutiques d'inhibiteurs de rtp801l
US7872119B2 (en) 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
WO2008148072A2 (fr) * 2007-05-24 2008-12-04 The Brigham And Women's Hospital, Inc. Variations genetiques liees a une maladies et methodes de detection et d'utilisation de ces variations
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
JP2012501167A (ja) * 2008-08-27 2012-01-19 オンコセラピー・サイエンス株式会社 膵臓癌関連遺伝子ｔｔｌｌ４
LT2398902T (lt) 2009-02-20 2023-12-27 Astellas Pharma Inc. Vėžio diagnostikos ir gydymo būdai bei kompozicijos
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
WO2011150400A1 (fr) * 2010-05-28 2011-12-01 New York Blood Center, Inc. Protéine de support nucléaire stip/tfip11 au titre de cible pour la thérapie anticancéreuse
EP2404936A1 (fr) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Thérapie du cancer utilisant des anticorps in vivo dirigés sur la cible CLDN6
US9321842B2 (en) 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
HUE053669T2 (hu) 2012-12-05 2021-07-28 Novartis Ag Készítmények és eljárások EPO-t célzó antitestekre
US10130649B2 (en) * 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
WO2015014376A1 (fr) 2013-07-31 2015-02-05 Biontech Ag Diagnostic et thérapie du cancer impliquant des cellules souches cancéreuses
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
IL270817B2 (en) 2017-05-24 2025-10-01 Thoeris Gmbh Use of glutamine synthetase to treat hyperammonemia
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
MX2021003663A (es) 2018-09-28 2021-05-28 Harvard College Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos.
JP7766904B2 (ja) * 2021-06-04 2025-11-11 地方独立行政法人東京都健康長寿医療センター 前立腺がん治療用医薬組成物
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016581A2 (fr) * 2000-08-24 2002-02-28 Genentech, Inc. Compositions et methodes pour le diagnostic et le traitement de tumeurs
JP2004520810A (ja) * 2000-08-24 2004-07-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
KR20030029847A (ko) * 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL/GENBANK/DDBJ 13 June 2001 (2001-06-13), STRAUSBERG, R.L. ET AL: "Homo sapiens papillary renal cell carcinoma", XP002446467, retrieved from EBI Database accession no. BC010450 *
WETERMAN MARIAN A J ET AL: "Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1) (p11;q21)-positive papillary renal cell carcinomas", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 26, 1996, pages 15294 - 15298, XP002446464, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
JP2006516192A (ja) 2006-06-29
AU2003303144A1 (en) 2004-07-29
WO2004060270A8 (fr) 2005-07-14
CA2503043A1 (fr) 2004-07-22
EP1578996A2 (fr) 2005-09-28
WO2004060270A2 (fr) 2004-07-22

Similar Documents

Publication Publication Date Title
EP1578996A4 (fr) Compositions et methodes pour diagnostiquer et traiter des tumeurs
EP1571968A4 (fr) Compositions et methodes permettant de diagnostiquer et de traiter une tumeur
EP1578371A4 (fr) Compositions et methodes de diagnostic et de traitement des tumeurs
EP1572091A4 (fr) Compositions et methodes de diagnostic et de traitement de tumeurs
EP1663259A4 (fr) Compositions et methodes de traitement du cancer
EP1696877A4 (fr) Methodes pour traiter la douleur
EP1701725A4 (fr) Methodes et compositions
EP1796666A4 (fr) Methodes et compositions de traitement de l'hyperlipidemie
EP1585482A4 (fr) Nouvelles compositions et methodes de traitement du psoriasis
EP1639090A4 (fr) Compositions et methodes de traitement et de diagnostic du cancer
EP1961065A4 (fr) Compositions et procedes pour diagnostiquer et traiter un cancer
EP1583504A4 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
EP1814909A4 (fr) Utilisation de aimp2dx2 pour diagnostiquer et traiter un cancer
EP1755391A4 (fr) Methodes et compositions de traitement de neuropathies
IL176259A0 (en) Compositions and methods for treating diabetes
EP1575580A4 (fr) Methodes de traitement de cancers
EP1660009A4 (fr) Methodes de traitement de l'endometriose
EP1576110A4 (fr) Compositions inhibant la migration cellulaire et methodes et compositions pour le traitement du cancer
EP1677735A4 (fr) Methodes et compositions pour moduler la fonction des adipocytes
NO20054711D0 (no) Fremgangsmater og farmasoytiske blandinger for palitelig oppnaelse av akseptable serum-testosteronnivaer
EP1575571A4 (fr) Compositions et methodes de diagnostic et de traitement d'une tumeur
NO20040058L (no) Innholdslesende apparat
EP1648474A4 (fr) Methodes et compositions pharmaceutiques pour cicatriser des lesions
EP1442062A4 (fr) Methodes de traitement du carcinome
EP1572118A4 (fr) Methodes et compositions de traitement de cancer au moyen des genes 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050425

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHOU, YAN

Inventor name: WU, THOMAS, D.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENENTECH, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20071119

17Q First examination report despatched

Effective date: 20080728

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090210